|
|
Volumn 22, Issue 2, 2004, Pages 64-66
|
|
On risk and plant-based biopharmaceuticals
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG PRODUCTS;
ECOLOGY;
PLANTS (BOTANY);
RISKS;
BLISTERING PACE;
PROTEINS;
ALPHA INTERFERON;
APROTININ;
CAPSID PROTEIN;
COLLAGEN;
ESCHERICHIA COLI ENTEROTOXIN;
HEPATITIS B SURFACE ANTIGEN;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
STREPTOCOCCUS ANTIGEN;
VIRUS GLYCOPROTEIN;
BIOTECHNOLOGY;
MEDICINAL PLANT;
PHARMACEUTICAL INDUSTRY;
RISK ASSESSMENT;
ALFALFA;
CARROT;
COST EFFECTIVENESS ANALYSIS;
DRUG INDUSTRY;
ECOLOGY;
ENVIRONMENTAL IMPACT;
ESCHERICHIA COLI;
HEALTH HAZARD;
HEPATITIS B VIRUS;
MAIZE;
NONHUMAN;
NORWALK GASTROENTERITIS VIRUS;
PLANT;
PLANT BIOTECHNOLOGY;
POTATO;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN PURIFICATION;
RABIES VIRUS;
RICE;
RISK ASSESSMENT;
SHORT SURVEY;
SOYBEAN;
STREPTOCOCCUS;
TOBACCO;
TOMATO;
TRANSGENIC PLANT;
VIRUS CAPSID;
DAUCUS CAROTA;
ESCHERICHIA COLI;
GLYCINE MAX;
HEPATITIS B VIRUS;
LYCOPERSICON ESCULENTUM;
MEDICAGO SATIVA;
NICOTIANA TABACUM;
NORWALK VIRUS;
RABIES VIRUS;
SOLANUM TUBEROSUM;
STREPTOCOCCUS;
ZEA MAYS;
|
|
EID: 1642563969
PISSN: 01677799
EISSN: None
Source Type: Journal
DOI: 10.1016/j.tibtech.2003.11.007 Document Type: Article |
|
Times cited : (63)
|
|
References (10)
|
